P57.04 Predicting Treatment Response to 1st- line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression

Authors :: Cheryl Ho
B. Melosky
Calum MacAulay
Stephen Lam
Rohan Abraham
M. Martin
Saeed Seyyedi
Ian Janzen
Ren Yuan
Source :: Journal of Thoracic Oncology. 16:S1138
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Treatment response
Oncology
business.industry
Cancer research
Medicine
non-small cell lung cancer (NSCLC)
Pembrolizumab
Line (text file)
business
medicine.disease

Tools